LB-100 plus Atezolizumab for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic).
- Your cancer has gotten worse after at least one standard treatment (like chemotherapy).
- Your tumor type is 'microsatellite stable' (MSS) – a common type that doesn't respond to some immunotherapies alone.
- You are healthy enough to have daily activities done without much help (ECOG score 0 or 1).
- You are willing to give extra blood samples and possibly a new tumor biopsy for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
Hear when a new Metastatic Microsatellite-stable Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.